For many investors, the main point of stock picking is to generate higher returns than the overall market. But in ...

Pfizer (NYSE: PFE) has been around for over 175 years, but it became a true household name during the COVID-19 pandemic as ...

Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment.

Over 100 major companies — including MicroStrategy, Coinbase, AMD, Pfizer, and Boeing — are set to report earnings today, July 31. From crypto and AI to healthcare and industrials, here's the full ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most ...

Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more ...

We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks ...

In the cutthroat pharmaceutical arena, Pfizer stands poised for a strategic pivot and a potential earnings bonanza in 2025.

US pharma giant Pfizer has criticized the recent inclusion of the company in the list of enterprises that should be denied ...

On July 30, 2025, Pfizer (PFE) saw its shares drop by 2.02%, with a trading volume hitting $0.86 billion and ranking 118th in ...

Income-focused investors actively pursuing high yielders should understand what they stand to sacrifice by reaching for a ...